Poolbeg Pharma signs exclusive deal with University College Dublin for vaccine candidate
- ByProactive Investors
- •
Poolbeg Pharma PLC operates as a biopharmaceutical company, engages in the development and commercialization of medicines for unmet medical needs in the United Kingdom. It develops POLB 001, which is in phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome and severe influenza. The company is also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; influenza and respiratory syncytial virus AI programme; POLB 002, an inlicensed firstinclass broad spectrum RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. In addition, it has a license to encapsulation technology for oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut. Further, the company is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Additionally, it has an option agreement with Silk Road Therapeutics to acquire topical muco-adherant pentoxifylline, an orphan drug candidate for Behçet’s disease. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.